Orexigen Therapeutics (NASDAQ: OREX) filed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Equity Offerings

RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60 March 16, 2016 9:46 AM Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from TakedaMarch 16, 2016 7:56 AM Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to NeutralMarch 16, 2016 6:35 AM JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market PerformMarch 16, 2016 6:34 AM Form S-3 Orexigen Therapeutics, March 15, 2016 5:25 PM Form 8-K Orexigen Therapeutics, For: Mar 15March 15, 2016 8:18 AM Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and EastMarch 15, 2016 7:05 AM